Review Article
Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes
Table 1
Type of immune infiltration in Lymphomas and prognosis.
| Type of lymphoma | Microenvironment | Prognosis |
| HL | activated CTLs (Granzyme B+) | Unfavourable | TIA-1+ cells | | FOXP3+ cells | |
| FL | Type 1 immune response pattern | Longer survival | T lymphocytes and regulatory T cells (FOXP3+) | Favourable outcome | Type 2 immune response pattern | Shorter survival | tumor-associated-macrophages (TAM, CD68+) and NK cells (CD57+) | Poor prognosis |
| DLBCL | activated CD4+ T cells, dendritic cells and macrophages | Better prognosis | Infiltrate greater than 20% of CD4+ cells, including CD45RO+ | | FOXP3+ | | Higher expression of Th1 than Th2 | | IL-6 (Th2 response) during the first weeks after the therapy | Predict complete remission | TILs-CD8+, activated CTLs | Poor prognosis |
| T and NK cell | monocytes | Poor prognosis | FOXP3+ | Unfavorable |
| ALCL | Granzyme B+ | Unfavorable | Granzyme B+ and lack of expression of ALK | Poor prognosis |
|
|